RECRUITING

Neuromodulation and Cognitive Training for Substance Use Disorders

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.

Official Title

Neuromodulation and Cognitive Training for Substance Use Disorders

Quick Facts

Study Start:2021-07-16
Study Completion:2025-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04426214

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment
  2. * Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.
  3. * Able to provide written consent and comply with study procedures.
  4. * Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).
  1. * Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)
  2. * Over 9 months of abstinence from substance use
  3. * A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
  4. * Presence of a condition that would render study measures difficult or impossible to administer or interpret
  5. * Age outside the range of 18 to 65
  6. * Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except for caffeine or nicotine (Nicotine use will be recorded but is not exclusionary)
  7. * Entrance to the treatment program under a court mandate. (i.e. legally incarcerated)
  8. * History of ECT or cortical energy exposure within the past 6 months, including participation in any other neuromodulation studies

Contacts and Locations

Study Contact

Melanie Stimac
CONTACT
612-301-2449
stima011@umn.edu

Principal Investigator

Kelvin Lim, MD
PRINCIPAL_INVESTIGATOR
University of Minnesota

Study Locations (Sites)

University of Minnesota Fairview
Minneapolis, Minnesota, 55454
United States

Collaborators and Investigators

Sponsor: University of Minnesota

  • Kelvin Lim, MD, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-16
Study Completion Date2025-09-01

Study Record Updates

Study Start Date2021-07-16
Study Completion Date2025-09-01

Terms related to this study

Keywords Provided by Researchers

  • tDCS
  • Cognitive Training
  • Plasticity

Additional Relevant MeSH Terms

  • Stimulant Use
  • Alcohol Use Disorder